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College of Pharmacy, Ewha Womans University, Seoul, Korea
Objectives: In recent years, a number of structurally diverse Histone deacetylase (HDAC) inhibitors have been identified and these HDAC
inhibitors induce growth arrest, differentiation and/or apoptosis of cancer cells in vitro and in vivo. This study aimed at investigating the anti-
tumor activity of newly synthesized HDAC inhibitor, 3-(4-dimethylamino phenyl)-N-hydroxy-2-propenamide (IN-2001) using human breast
cancer cells. 
Methods: We have synthesized a new HDAC inhibitor, IN-2001, and cell proliferation inhibition assay with this chemical in estrogen
receptor-positive human breast cancer MCF-7 cells. Cell cycle analysis on MCF-7 cells treated with IN-2001 was carried out by flow
cytometry and gene expression was measured by RT-PCR. 
Results: In MCF-7 cells IN-2001 showed remarkable anti-proliferative effects in a dose- and time-dependent manner. In MCF-7 cells, IN-
2001 showed a more potent growth inhibitory effect than that of suberoylanilide hydroxamic acid. These growth inhibitory effects were
related to the cell cycle arrest and induction of apoptosis. IN-2001 showed accumulation of cells at G2/M phase and of the sub-G1population
in a time-dependent manner, representing apoptotic cells. IN-2001-mediated cell cycle arrest was associated with HDAC inhibitor-mediated
induction of CDK inhibitor expression. In MCF-7 cells, IN-2001 significantly increased p21
WAF1expression. 
Conclusions: In summary, cyclin-dependent kinase (CDK) induced growth inhibition, possibly through modulation of cell cycle and apoptosis
regulatory proteins, such as CDK inhibitors, and cyclins. Taken together, these results provide an insight into the utility of HDAC inhibitors as
a novel chemotherapeutic regime for hormone-sensitive and insensitive breast cancer. 
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INTRODUCTION
Breast cancer is the major cancer affecting females around
the world today. In Korea, breast cancer incidence has been
continuously increasing and in 2002, breast cancer became the
most common form of cancers among Korean women.
According to the American Cancer Society 2005 report [1],
breast cancer is the most frequent cancer in women of the
United States. In the United States alone, currently around
40,000 female and 1,500 male breast cancer deaths occur per
annum. Current therapeutic approaches for human breast cancer
include hormonal therapy with anti-estrogenic compounds, as
well as surgery, radiotherapy, hyperthermia, and chemotherapy
[2]. However, conventional strategies for treatment of breast
cancer are still unsatisfactory and limited. Therefore, there is an
urgent need to develop more effective therapeutic approaches
for prevention and treatment of breast cancer.
Recently, histone deacetylase has been discovered as a
potential target for the development of new therapeutic
agents. Recent data suggested that histone deacethlase
(HDAC) inhibitors displayed potent anti-tumor activity via cell
cycle arrest, differentiation, and induction of apoptosis in the
various tumor cells, whereas they showed low or negligible
effects on the untransformed cells [3-8]. These selective
inhibitory effects on the transformed cells compared with normal
cells are not completely understood. However, they do not appear
to be caused by a difference in the ability to inhibit HDAC
activity because they cause a similar accumulation of acetylated
histone proteins in both normal and tumor cells [9-13]. Another
important characteristic of HDAC inhibitors is their selectivity in
altering gene expression in transformed cells. Several studies
have now revealed that fewer than 10% of expressed genes in a
given malignant cell are affected by HDAC inhibitors, with a
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Open Accessnear equal number of transcriptionally active genes being
suppressed as being stimulated. 
The report showed that tumor-associated proteins mediated
proliferation and cell cycle progression, survival factors,
growth factor receptors, kinases, signal transduction
intermediates, DNA synthesis/repair enzymes, shuttling
proteins, transcription factors, and protease. Recently, HDAC
inhibitors have become an exciting new class of drugs that
have been targeted as anti-cancer agents [14-16]. A number
of clinical trials have shown the utility of HDAC inhibitors in
treatment of tumors. However, the accurate molecular basis
for their anti-cancer activity remains largely unknown. 
In this study, we tried to evaluate the anti-tumor effects of
various HDAC inhibitors on MCF-7 human breast cancer.
Moreover, the underlying chemotherapeutic mechanisms of
them were also explored. To examine the anti-tumor effect
of HDAC inhibitors, we examined the effect of HDAC
inhibitors on the cell proliferation, cell cycle distribution, and
apoptosis in MCF-7 human breast cancer cells. To find out
the mechanism of anti-tumor activity of HDAC inhibitors,
we examined the effect of IN-2001 on the expression of cell
cycle regulatory protein and apoptosis-related proteins.
MATERIALS AND METHODS
I. Chemicals 
HDAC inhibitors, such as Trichostatin A, IN2001,
suberoylanilide hydroxamic acid (SAHA), and ((E)-N-
hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-
yl0ethyl)amino]methyl]phenyl]prop-2-enamide (LAQ) were
generously provided from Dr. Kim (Ewha Womans
University, Seoul, Korea). Helminthosporium carbonum
(HC) toxin was obtained from Sigma Chemical Co. (St.
Louis, MO, USA). 
II. Cell Lines and Cell Culture Conditions
MCF-7 cells were obtained from Korean Cell Line Bank
(Seoul, Korea). MCF-7 cells were maintained in Minimum
Essential Medium (Garlsbat, CA USA), supplemented with
fetal bovine serum, insulin and penicillin-streptomycin. Cells
were routinely maintained at 37 and in 5 % CO2.
III. Cell Proliferation Assay 
Cells were plated in 96 well plates at a density of 10
4 cells
per well. The following day, the cells were treated with
chemicals. The number of cells was measured based on the
modified sulforhodamine B (SRB) assay of Soto et al. [17].
Cells were treated with cold 10% trichloroacetic acid (TCA)
and incubated at 4 C for 30 minutes, then washed five times
with tap water and left to dry. TCA-fixed cells were stained
for 30 minutes with 0.4 % (w/v) SRB dissolved in 1 % acetic
acid. Wells were washed with tap water and air-dried. Bound
dye was solubilized with 10 mM tris base (pH 10.5) in a
shaker for 30 minutes, Finally, optical density was read using
ELISA reader (Bio-Rad, Hercules, CA, USA) at 570 nm. 
IV. Fluorescent Activated Cell Sorter (FACS) Analysis
Cells were plated in 60 mm
2 dishes and exposed to
chemicals. Treated cells were detached using trypsin-EDTA
and fixed with 70% ethanol. After centrifugation, the cells were
treated with RNase A (10  g/mL) for 20 minutes at 37 and
stained with propidium iodide (2  g/mL) for 30 minutes at 37
in the dark. The DNA content per cell was evaluated in a
FACSCalibur (Becton Dickinson, San Diego, CA, USA).  
V. RT-PCR Analysis 
Cells were plated in 60 mm
2 dishes and exposed to chemicals
for 24 hours. Total RNA was extracted using trizol reagent
(Invitrogen Co., Carlsbad, CA, USA). Reverse transcription
was carried out on 3  of total RNA diluted in a 22.5  L
mixture containing 1  L random primer (0.5  / L), 1  L
dNTP (1 mM), 2  L DTT, 4  L RT buffer (5X), 1  L M-MLV
reverse transcriptase (200 U/ L), 0.5  L RNasin (40 U/ L),
and H2O. After incubation at 37 for 1 hour, the reverse
transcriptase was inactivated for 10 minutes at 95 and cDNA
was stored at -20 or immediately used for PCR. One L of the
synthesized cDNA was subjected to PCR amplification with
primer (GAPDH; 5’ ACATCgCTCA gACACCATgg3’; 5’
gTAgTTgAggTCAATgAAggg 3: p21; 5’ gAACTTCgACT
TTgTCACCgAg3’; 5’ CgTTTTC gACCCTgAgAgTCTC
3’: Cyclin D1; 5’ AgCCATggAACACCAgCTC3’; 5’ gCAC
CTCCAgCATCCAggT3’ in a 10  L reaction containing
dNTP and Taq polymerase. DNA was denatured at 95 for
5 minutes and cycled immediately 25 times at 95 for 30
seconds with specific annealing temperature chosen by
preliminary experiments and extended at 72 for 1 minute.
The PCR reaction ended with 5 min incubation at 72 .
PCR products were analyzed on 2% agarose gels and the
image of the band on agarose gel was quantified using
CoreImager MC2000 (Sam Learmdro, CA USA). 
RESULTS
I. IN-2001 Inhibits Human Breast Cancer MCF-7
Cell Growth 
In recent years, an increasing number of structurally
diverse HDAC inhibitors have been identified as an exciting
new class of potential anti-cancer agents. In this study, we
evaluated the anti-tumor effects of various kinds of HDAC
inhibitors in the human breast cancer cells in an attempt to
find out better therapeutic agents for breast cancer treatment.
To determine the anti-proliferative effect of IN-2001 (Figure
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were treated with vehicle (0.1% DMSO) or various
concentrations (0.001  M to 100  M) of IN-2001 for
various times and then the number of cells was determined
based on the SRB assay. As shown in Figure 2, IN-2001
showed an anti-proliferative effect in a dose- and time-
dependent manner. The IC50 value of IN-2001 was 0.287 
M at 72 hours treatment of IN-2001 in MCF-7 cells (Table
1). MCF-7 cells showed significant growth inhibition when
cells were exposed to IN-2001 for more than 24 hours, and
24 hours treatment resulted in 15-20% with up to a 10  M
IN-2001 reduction of cell proliferation compared to control.
IN-2001 treatment for 48 hours and 72 hours resulted in a
potent dose-dependent inhibition of MCF-7 cell proliferation
(Figure 2A). 
II. SAHA Inhibits Human Breast Cancer MCF-7 Cell
Growth 
In the next experiment, we examined the effect of SAHA
as a reference HDAC inhibiting drug on MCF-7 cell
proliferation and the result is shown in Figure 3. SAHA
decreased the proliferation of human breast cancer cells in a
time- and dose-dependent manner. MCF-7 cells showed
significant growth inhibition when cells were exposed to
SAHA for more than 24 hours. In MCF-7 cells, SAHA
treatment for 24 hours resulted in a 15-20% reduction of cell
proliferation compared to the control. SAHA treatment for
48 hours and 72 hours resulted in potent dose-dependent
inhibition of MCF-7 cell proliferation (Figure 2B). The IC50
value of SAHA was 0.761  M at 72 hours treatment of IN-
2001 in MCF-7 cells (Table 1).
III. IN-2001-Induced Cell Cycle Arrest
To investigate the growth inhibitory effects of IN-2001 on
cell cycle alteration, we analyzed the cell cycle distribution
in human breast cancer cells. MCF-7 cells were treated
without or with 1  M IN-2001 or SAHA for 24 or 48 hours,
and then cell cycle distribution was analyzed by flow
cytometric analysis after propidium iodide staining of
cellular DNA. Representative histograms and quantitative
analysis data are shown in Figure 3. 
In MCF-7 cells, HDAC inhibitors except for SAHA
induced G2/M arrest after 24 hours and 48 hours treatments
(Figure 3A). When cells were treated with IN-2001 and
SAHA for 24 hours, MCF-7 cells yielded 30.6% and 7.9%
of cells in G2/M phase, respectively, whereas untreated
control cells showed 6.1% of cells in G2/M phase. At 48
hours treatment, IN-2001 and SAHA accumulated 20.4%
and 37.0% of cells in G2/M phase, respectively, whereas
untreated control cells showed 3.9% of cells in G2/M phase.
SAHA showed a different cell cycle alteration: G0/G1 arrest.
At 24 hours and 48 hours treatment, SAHA accumulated
61.2% and 71.4% of cells in G0/G1 phase, respectively,
whereas untreated control cells showed 53.2% and 63.8% of
cells in G0/G1 phase, respectively (Figure 3B and 3C).
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Figure 2. Inhibition of MCF-7 cell proliferation. MCF-7 human breast cancer cells were treated with vehicle (0.1% DMSO) or
indicated concentrations (0.001  M to 10  M) of IN-2001 (A) or indicated concentrations (0.001  M to 10  M) of SAHA (B) for
various exposure times (0 to 72 hour). The number of cells was determined by SRB assay and cell proliferation was expressed
as a percentage of the control. 
Values are presented as mean SD (N=4). 
IN-2001, 3-(4-dimethylamino phenyl)-Nhydroxy-2-propenamide; SAHA, suberoylanilide hydroxamic acid, SRB, sulforhodamine B.
Figure 1.Structure of HDAC inhibitors.
HDAC, Histone deacetylase; IN-2001, 3-(4-dimethylamino phenyl)-N-
hydroxy-2-propenamide;  SAHA, suberoylanilide hydroxamic acid.
Table 1.Fifty percent inhibitory concentration of IN-2001 in MCF-7





HDAC, Histone deacetylase; IN-2001, 3-(4-dimethylamino phenyl)-N-
hydroxy-2-propenamide;  SAHA, suberoylanilide hydroxamic acid.IV. IN-2001-Induced Apoptosis 
In addition to cell cycle arrest, HDAC inhibitors have been
shown to induce apoptosis in various human cancer cell lines
(18 ). After 72 hours treatment of IN-2001, the extensive
floating dead cells were observed in a dose-dependent
manner in MCF-7 (Figure 4). These observations prompted
us to examine whether the effects of IN-2001 on cell death
were attributable to the induction of apoptosis. We performed
FACS analysis of propidium iodide-stained nuclei to assess
the presence of a hypodiploid or sub-G1 population resulting
from DNA fragmentation. MCF-7 cells were treated without
or with 1  M IN-2001 for 24 or 48 hours and then stained
with PI, and subjected to FACS analysis. 
As shown in Figure 3, increasing exposure times of IN-
2001, and SAHA led to an incremental accumulation of the
apoptotic sub-G1 population in both sets of MCF-7 cells. 
FACS analysis revealed that untreated MCF-7 cells
showed 1.0% of sub-G1 population, but exposure of 1  M
IN-2001 for 24 hours increased the sub-G1 population to be
4.4%. When MCF-7 cells were treated with IN-2001 for 48
hours, 16.8-32.3% of apoptotic cells were observed, whereas
untreated cells showed 0.5% of sub-G1 population.
However, 1  M SAHA did not show apparent sub-G1
population. As shown in Figure 4, IN-2001 and other HDAC
inhibitors were found to induce cell cycle arrest and
apoptosis in human breast cancer cells. Because acetylation
and deacetylation of histones have been shown to play an
important role in the regulation of gene expression in
eukaryotic cells, cell cycle arrest and apoptosis by HDAC
inhibitors might be attributable to alteration of genes
involved in cell cycle progression and apoptosis. To test this
possibility, we examined the effects of IN-2001 and other
HDAC inhibitors on cell cycle and apoptosis-related gene
expression in human breast cancer cell lines. 




WAF1 is a CDK inhibitor that binds to CDK complexes
and decreases kinase activity and may act as a key regulator
of the cell cycle and apoptosis. Therefore, we examined the
effects of IN-2001 and SAHA on the expression of p21
WAF1
in human breast cancer cells. MCF-7 cells were treated with
1  M IN-2001 or SAHA for 24 hours, and then analyzed for
p21
WAF1 mRNA level by RT-PCR. As shown in Figure 5A,
exposure of MCF-7 cells to 1  M HDAC inhibitors induced
upregulation of p21
WAF1 mRNA levels, as determined by RT-
PCR analysis. In MCF-7 cells, IN-2001, TSA, SAHA, LAQ,
and HC-toxin increased p21
WAF1 mRNA levels by 193.6%,
255.7%, 128.6%, 266.0%, and 231.1%, respectively. A
dose-dependent experiment for mRNA levels of p21
WAF in
MCF-7 cells treated with IN-2001 is shown in Figure 5B. In
MCF-7 cells, p21
WAF1 mRNA levels were induced by
152.7%, 168.8%, and 180.8% at 0.1  M, 0.5  M, and 1  M
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Figure 3. (A) Effects of IN-2001 and other HDAC inhibitors
on the cell cycle distribution. MCF-7 cells were exposed to
1  M IN-2001 or SAHA for 24 or 48 hour, after which they
were isolated, fixed, stained with PI, and subjected to cell
cycle analysis using a flow cytometer. MCF-7 cells were
exposed to 1  M IN-2001 (B) or SAHA (C) for 24 or 48 hour,
after which they were isolated, fixed, stained with PI, and
subjected to cell cycle analysis using a flow cytometer. The
percentages of cells distributed in the sub-G1, G0/G1, S, and
G2/M phases were calculated by the ModFit program.
HDAC, Histone deacetylase; IN-2001, 3-(4-dimethylamino phenyl)-
Nhydroxy-2-propenamide; SAHA, suberoylanilide hydroxamic acid.
IN-2001
00 . 0 1 0 . 1 1 1 0
SAHA
Figure 4. Morphological changes by IN-2001 and SAHA.
MCF-7 cells were incubated with the indicated
concentrations of HDAC inhibitors for 72 hours. Cells were
then observed under the phase-contrast microscope and
directly photographed (magnification, X200).
HDAC, Histone deacetylase; IN-2001, 3-(4-dimethylamino phenyl)-
Nhydroxy-2-propenamide; SAHA, suberoylanilide hydroxamic acid.IN-2001, respectively. These results suggest that
upregulation of CDK inhibitors by IN-2001 may lead to cell
cycle arrest, ultimately resulting in growth inhibition. 
VI. IN-2001 Downregulated Cyclin D1 Expression
Cyclin D1 is involved in regulation of transition from G1 to
S during the cell cycle. Given the critical role of cyclin D1 in
cell cycle regulation, their abnormal or untimely expression
could disrupt the cell cycle and therefore render them growth-
promoting genes or oncogenes. Thus, cyclin D1 is considered
to be a putative proto-oncogene and is overexpressed in a
number of tumor types including lymphomas, breast cancer,
and thyroid carcinoma. Herein, we investigated if IN-2001
and other HDAC inhibitors can regulate the expression of
cyclin D1 in human breast cancer cells. MCF-7 cells were
treated without or with one  M HDAC inhibitors for 24
hours, and then analyzed for cyclin D1 mRNA levels by RT-
PCR analysis. As shown in Figure 6A, cyclin D1 mRNA
was detectable in untreated MCF-7 and  M HDAC inhibitor
treatment suppressed the expression of cyclin D1 mRNA in
MCF-7 cells. IN-2001, TSA, LAQ, and HC-toxin resulted in
reductions to 82.1%, 30.4%, 34.6%, and 91.1% in cyclin D1
expression, respectively. 1  M of SAHA, however, did not
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Figure 5. Effects of IN-2001 and other HDAC inhibitors on the expression of CDK inhibitors. (A) MCF-7 cells were treated without
(0.1% DMSO) or with 1  M HDAC inhibitors for 24 hour (B) MCF-7 cells were treated without (0.1% DMSO) or with increasing
concentrations (0.1-10  M) of IN-2001 for 24 hour. RT-PCR analysis of p21
WAF1 mRNA levels. Total RNA was isolated, subjected
to RT-PCR using specific primers, and then fractionated on 2% agarose gel. GAPDH was used as a loading control.
HDAC, Histone deacetylase; IN-2001, 3-(4-dimethylamino phenyl)-Nhydroxy-2-propenamide; CDK, cyclin-dependent kinase; SAHA, suberoylanilide
hydroxamic acid; TSA, trichloroacetic acid; LAQ, ((E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl0ethyl)amino]methyl]phenyl]prop-2-enamide; HC,
Helminthosporium carbonum. 
*p<0.05. 
Figure 6. Effects of IN-2001 and other HDAC inhibitors on the expression of cyclin D1. (A) MCF-7 cells were treated without
(0.1% DMSO) or with 1  M HDAC inhibitors for 24 hour (B) MCF-7 cells were treated without (0.1% DMSO) or with increasing
concentrations (0.1-10  M) of IN-2001 for 24 hour. Total RNA was isolated, subjected to RT-PCR using specific primers, and
then fractionated on 2% agarose gel. GAPDH was used as a loading control for quantification, the band intensity of cyclin D1
was normalized to that of  control and data was expressed as a relative percent compared to the control group.
HDAC, Histone deacetylase; IN-2001, 3-(4-dimethylamino phenyl)-Nhydroxy-2-propenamide; CDK, cyclin-dependent kinase; SAHA, suberoylanilide
hydroxamic acid; TSA, trichloroacetic acid; LAQ, ((E)-N-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1H-indol-3-yl0ethyl)amino]methyl]phenyl]prop-2-enamide; HC,
Helminthosporium carbonum. 
*p<0.05. change cyclin D1 expression. A dose-dependent experiment
for levels of cyclin D1 in MCF-7 cells treated with IN-2001
is shown in Figure 6B. The expression of cyclin D1 mRNA
was downregulated in a dose-dependent manner by
treatment with doses of 0.1-10  M of IN-2001. In MCF-7
cells, cyclin D1 levels were suppressed by 84.1%, 56.1%,
and 40.7% at 0.1, 0.5, and 1  M IN-2001, respectively.
Taken together, these results demonstrate that specific
changes in the expression of cell cycle-related genes may
lead to cell cycle arrest, ultimately resulting in growth
inhibition via upregulation of p21
WAF1, and downregulation of
cyclin D1 in human breast cancer cells.
DISCUSSION
In this study, we reported that IN-2001 HDAC inhibitor
effectively inhibited the proliferation of human breast cancer
cells. Previous data, published on MCF-7 and MDA-MB-
231 cells using TSA or sodium butyrate as an inhibitor of
HDAC, also supported a higher sensitivity of ER-positive
breast cancer cells [18]. This differential response was not
associated with a modification of drug efflux via the
multidrug resistance system or with a global modification of
HAT/HDAC activities [18-24]. They suggested that p21
WAF1
gene expression, in relation with ER , could play a role in
this differential response of breast cancer cells to
hyperacetylating agents. In ER-positive breast cancer cells,
the p21
WAF1 gene was more sensitive to TSA regulation and
was expressed at higher levels. Moreover, the re-expression
of ER following adenoviral infection of ER-negative breast
cancer cells increased both growth inhibitory activity of TSA
and p21
WAF1 protein accumulation. In the current study, we
found that HDAC inhibitors induced the expression of CDK
inhibitor, such as p21
WAF1 and the induction of p21
WAF1 was
highly correlated with the growth inhibitory effect of HDAC
inhibitors. Further studies are needed to clarify the
implications of ER status in the regulation of p21
WAF1 by
HDAC inhibitors. 
HDAC inhibitors have been reported to induce apoptosis
in various human cancer cell lines, such as MCF-7 breast
cancer [25], small lung cancer [26], HOS osteosarcoma [27],
and HCT116 colon cancer [28]. Ruefli et al. [29] and Rosato
et al. [30] suggested that HDAC inhibitor-induced apoptosis
involved two different mechanisms, the intrinsic pathway
and the extrinsic pathway. The relative importance of these
two pathways depends on the cell type and class of HDAC
inhibitors used. In previous study, HDAC inhibitors
effectively induced apoptosis in a dose-dependent manner,
as visualized by FACS analysis. At the same time, HDAC
inhibitors activated caspase 3/7 and increased cytochrome C
release, which was accompanied by the increase of the
relative ratio of Bax/Bcl-2 [31-33]. These findings indicate
that HDAC inhibitor may induce caspase-dependent
apoptosis partially through the mitochondrial pathway,
accompanied by an increased ratio of Bax/Bcl-2 and
cytochrome C release. In particular, MDA-MB-231 cells
treated with HDAC inhibitor showed strong activation of the
intrinsic pathway. The implication of the extrinsic pathway
in HDAC inhibitor-induced apoptosis had not been
determined in this study. To make this clear, further studies
are required, including examination on the death receptor
activity and the initiator caspases (e.g., caspase 8 and caspase
9) activation. In addition, HDAC inhibitors increased ROS
induction. In particular, remarkable induction of ROS
generation was observed with TSA and LAQ, which showed
potent growth inhibitory effects and inducibility of apoptosis
[34]. These data are compatible with the notion that HDAC
inhibitors are potent inducers of ROS and that induced ROS
are important in the HDAC inhibitor-mediated apoptosis.
Considering the role of p21
WAF1 as a negative regulator of
cell cycle progression, our observation that HDAC inhibitors
commonly induced p21
WAF1 expression both in vivo and in
vitro breast cancer model, designating a possible anti-tumor
mechanism of HDAC inhibitors. HDAC inhibitors up-
regulate the expression of p21
WAF1 and increased p21
WAF1 may
trigger cell cycle arrest, resulting in inhibition of cell
proliferation. In summary, IN-2001 HDAC inhibitor
inhibited human breast cancer MCF-7 cell proliferation via
cell cycle arrest at G2/M arrest as well as an increase in
apoptosis.
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